A New Chapter in Obesity Treatment: Mechanisms and Clinical Research Progress of Multi-target Peptide Agonists

doi:10.12114/j.issn.1007-9572.2025.0372

Chinese General Practice ›› 2026, Vol. 29 ›› Issue (12): 1511-1519.DOI: 10.12114/j.issn.1007-9572.2025.0372

• "Year of Weight Management"·Weight Loss Section • Previous Articles Next Articles

A New Chapter in Obesity Treatment: Mechanisms and Clinical Research Progress of Multi-target Peptide Agonists

1. Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, China
2. Department of Knee and Joint Orthopedics, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine/Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China
3. Department of Operating Room, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine/Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China
4. Department of Orthopedic, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine/Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China

Received:2025-08-10 Revised:2025-12-01 Published:2026-04-20 Online:2026-03-12
Contact: LI Xiang

肥胖症治疗的新篇章：多靶点肽类激动剂的机制与临床研究进展

1．510405　广东省广州市，广州中医药大学第二临床医学院
2．510120　广东省广州市，广州中医药大学第二附属医院　广东省中医院膝骨关节科
3．510120　广东省广州市，广州中医药大学第二附属医院　广东省中医院手术室
4．510120　广东省广州市，广州中医药大学第二附属医院　广东省中医院骨科教研室

通讯作者: 李想
作者简介:
作者贡献：
颜漫丽提出研究思路，参与文献整理，负责论文起草与修订，对稿件整体负责；张葆青、黄磊参与论文起草；李想参与论文修订。
基金资助:
2021年岐黄学者支持项目(国中医药人教司〔2022〕6号); 林定坤广东省名中医传承工作室项目(0103030912)

Abstract

Abstract:

Obesity is a chronic and relapsing disease resulting from interactions between genetic and environmental factors. Its global prevalence continues to rise, making it a major public health challenge. Traditional weight management strategies often yield suboptimal outcomes. In recent years, peptide-based therapies targeting the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR) have advanced rapidly, with multi-target agonists emerging as a promising new therapeutic trend. This review systematically summarizes the mechanisms and clinical progress of these agents: GLP-1R single-target agonists demonstrate significant efficacy in weight reduction, glycemic control, and multi-organ protection, though interindividual variability and gastrointestinal side effects remain limitations. Dual agonists targeting GLP-1R/GIPR and GLP-1R/GCGR (e.g., Tirzepatide, Mazdutide) further improve metabolic parameters, reduce liver fat, and mitigate cardiovascular risks through synergistic regulation of appetite, energy expenditure, and lipid metabolism. Meanwhile, the triple agonist Retatrutide (targeting GLP-1R/GIPR/GCGR) shows robust potential for weight loss and body composition improvement, while also modulating key lipid metabolic regulators such as ANGPTL3/8, thereby broadening the therapeutic horizon for metabolic diseases. Looking forward, the development of multi-target agents-combined with long-acting formulation technologies, precise subtyping, and individualized treatment strategies-is expected to significantly enhance the efficacy and safety of obesity treatments and alleviate the public health burden.

Key words: Obesity, Multi-target peptide agonists, Glucagon-like peptide-1 receptor, Glucose-dependent insulinotropic polypeptide receptor, Glucagon receptor

摘要：

肥胖症是一种由遗传与环境因素交互作用导致的慢性、复发性疾病，全球患病率持续上升，已成为重大公共卫生挑战。传统体重管理策略效果有限，近年来以胰高血糖素样肽1受体（GLP-1R）、葡萄糖依赖性促胰岛素多肽受体（GIPR）和胰高血糖素受体（GCGR）为靶点的肽类药物快速发展，尤其多靶点激动剂逐渐成为治疗新趋势。本文系统介绍了该类药物的作用机制与临床研究进展：GLP-1R单靶点激动剂在减重、降糖及多器官保护中显示显著效果，但仍存在个体差异和胃肠道不良反应；GLP-1R/GIPR及GLP-1R/GCGR双靶点激动剂（如替尔泊肽、玛仕度肽）通过协同调控摄食、能量消耗和脂代谢，进一步改善代谢指标并减轻肝脏脂肪及心血管风险；而GLP-1R/GIPR/GCGR三重激动剂瑞他鲁肽更展现出强劲的减重与身体成分优化潜力，同时调节血管生成素样蛋白3/8（ANGPTL3/8）等脂代谢关键因子，拓宽了代谢性疾病的治疗前景。展望未来，多靶点药物研发结合长效制剂技术、精准分型及个体化治疗策略，有望显著提升肥胖症的治疗效果与用药安全性，减轻公共健康负担。

关键词: 肥胖症, 多靶点肽类激动剂, 胰高血糖素样肽1受体, 葡萄糖依赖性促胰岛素多肽受体, 胰高血糖素受体

CLC Number:

R 589.25

YAN Manli,ZHANG Baoqing,HUANG Lei, et al. A New Chapter in Obesity Treatment: Mechanisms and Clinical Research Progress of Multi-target Peptide Agonists[J]. Chinese General Practice, 2026, 29(12): 1511-1519. DOI: 10.12114/j.issn.1007-9572.2025.0372.
颜漫丽,张葆青,黄磊等. 肥胖症治疗的新篇章：多靶点肽类激动剂的机制与临床研究进展[J]. 中国全科医学, 2026, 29(12): 1511-1519. DOI: 10.12114/j.issn.1007-9572.2025.0372.

Figures/Tables 1

References 91

[1]	KHANI M, AFSAHI R, NASAB A E, et al. Addressing the challenge of obesity in primary care: a review of effective interventions and implementation strategies[J]. Diabetol Metab Syndr, 2025, 17(1): 351. DOI: 10.1186/s13098-025-01925-z.
[2]	中华医学会内分泌学分会, 赵家军, 纪立农, 等. 肥胖患者的长期体重管理及药物临床应用指南(2024版)[J]. 中华内分泌代谢杂志, 2024, 40(7): 545-564.
[3]	ARON-WISNEWSKY J, WARMBRUNN M V, NIEUWDORP M, et al. Metabolism and metabolic disorders and the microbiome: the intestinal microbiota associated with obesity, lipid metabolism, and metabolic health-pathophysiology and therapeutic strategies[J]. Gastroenterology, 2021, 160(2): 573-599. DOI: 10.1053/j.gastro.2020.10.057.
[4]	ZHANG J, ANDERSEN C, OLSEN A, et al. Life-long body mass index trajectories and cardiometabolic biomarkers-the Danish diet, cancer, and health-next generations cohort[J]. Int J Obes, 2025, 49(11): 2311-2319. DOI: 10.1038/s41366-025-01882-7.
[5]	LOSEV V, LU C, TAHASILDAR S, et al. Sex-specific body fat distribution predicts cardiovascular ageing[J]. Eur Heart J, 2025: ehaf553. DOI: 10.1093/eurheartj/ehaf553.
[6]	HAWES M L, MOODY M A, MCCAULEY C R, et al. Oncogenic effects of ECM remodeling in obesity and breast cancer[J]. Oncogene, 2025, 44(37): 3409-3421. DOI: 10.1038/s41388-025-03521-x.
[7]	LEE M K, HEO J, AHN J, et al. Cumulative abdominal obesity exposure and progressive risk of endometrial cancer in young women: a nationwide cohort study[J]. Int J Obes, 2025, 49(10): 2094-2101. DOI: 10.1038/s41366-025-01862-x.
[8]	HE Q, ZHANG J N, MAN Z T, et al. Association between central obesity and the risk of glenohumeral joint osteoarthritis: a prospective study[J]. J Shoulder Elbow Surg, 2025: S1058-2746(25)00606-8. DOI: 10.1016/j.jse.2025.07.007.
[9]	ANNUNZIATA G, ZONZINI G B, FRIAS-TORAL E, et al. Beyond dietary therapy: addressing weight stigma awareness in medical students[J]. J Transl Med, 2025, 23(1): 951. DOI: 10.1186/s12967-025-06981-7.
[10]	KULA A, BRENDER R, BERNARTZ K M, et al. Waist circumference as a parameter in school-based interventions to prevent overweight and obesity-a systematic review and meta-analysis[J]. BMC Public Health, 2024, 24(1): 2864. DOI: 10.1186/s12889-024-20354-7.
[11]	CHEW H S J, DALAKOTI M, LEOW M K S, et al. Waist circumference remains the better predictor of insulin resistance compared to 2025 Lancet Commission definition on clinical obesity[J]. Diabetes Obes Metab, 2025, 27(11): 6775-6778. DOI: 10.1111/dom.70052.
[12]	LIAO J H, WANG L J, DUAN L, et al. The association between waist circumference, weight-adjusted waist index, waist-to-height ratio and waist divided by height 0.5 and the prevalence of cardiovascular diseases in patients with diabetes[J]. BMC Public Health, 2025, 25(1): 2835. DOI: 10.1186/s12889-025-24068-2.
[13]	NIU Y, ZHANG Y J, SHENG J Y, et al. Triponderal mass index can be used as a potential tool to predict the risk of hyperuricemia in children and adolescents with obesity: a population-based study[J]. Front Nutr, 2025, 12: 1544209. DOI: 10.3389/fnut.2025.1544209.
[14]	LIN Z W, FENG W H, LIU Y J, et al. Machine learning to identify metabolic subtypes of obesity: a multi-center study[J]. Front Endocrinol (Lausanne), 2021, 12: 713592. DOI: 10.3389/fendo.2021.713592.
[15]	YAN L H, LI J X. The central nervous system control of energy homeostasis: high fat diet induced hypothalamic microinflammation and obesity[J]. Brain Res Bull, 2022, 185: 99-106. DOI: 10.1016/j.brainresbull.2022.04.015.
[16]	QIU S, WU Q N, WANG H, et al. AZGP1 in POMC neurons modulates energy homeostasis and metabolism through leptin-mediated STAT3 phosphorylation[J]. Nat Commun, 2024, 15(1): 3377. DOI: 10.1038/s41467-024-47684-9.
[17]	RUSSO B, MENDUNI M, BORBONI P, et al. Autonomic nervous system in obesity and insulin-resistance-the complex interplay between leptin and central nervous system[J]. Int J Mol Sci, 2021, 22(10): 5187. DOI: 10.3390/ijms22105187.
[18]	AHMED B, SULTANA R, GREENE M W. Adipose tissue and insulin resistance in obese[J]. Biomed Pharmacother, 2021, 137: 111315. DOI: 10.1016/j.biopha.2021.111315.
[19]	ENGIN A B. Mechanism of obesity-related lipotoxicity and clinical perspective[M]// Obesity and Lipotoxicity. Cham: Springer International Publishing, 2024: 131-166. DOI: 10.1007/978-3-031-63657-8_5.
[20]	ENGIN A. Lipid storage, lipolysis, and lipotoxicity in obesity[J]. Adv Exp Med Biol, 2024, 1460: 97-129. DOI: 10.1007/978-3-031-63657-8_4.
[21]	WANG H, YE J P. Regulation of energy balance by inflammation: common theme in physiology and pathology[J]. Rev Endocr Metab Disord, 2015, 16(1): 47-54. DOI: 10.1007/s11154-014-9306-8.
[22]	SANTACRUZ-CALVO S, BHARATH L, PUGH G, et al. Adaptive immune cells shape obesity-associated type 2 diabetes mellitus and less prominent comorbidities[J]. Nat Rev Endocrinol, 2022, 18(1): 23-42. DOI: 10.1038/s41574-021-00575-1.
[23]	LIU X, HUH J Y, GONG H, et al. Lack of mature lymphocytes results in obese but metabolically healthy mice when fed a high-fat diet[J]. Int J Obes (Lond), 2015, 39(10): 1548-1557. DOI: 10.1038/ijo.2015.93.
[24]	FRANSSEN W M A, NIESTE I, VERBOVEN K, et al. Sedentary behaviour and cardiometabolic health: integrating the potential underlying molecular health aspects[J]. Metabolism, 2025, 170: 156320. DOI: 10.1016/j.metabol.2025.156320.
[25]	JI Y N, LI M, CHANG M Y, et al. Inflammation: roles in skeletal muscle atrophy[J]. Antioxidants (Basel), 2022, 11(9): 1686. DOI: 10.3390/antiox11091686.
[26]	SONTICHAI W, DEJKHAMRON P, POTHACHAROEN P, et al. Subtle inflammation: a possible mechanism of future cardiovascular risk in obese children[J]. Korean J Pediatr, 2017, 60(11): 359-364. DOI: 10.3345/kjp.2017.60.11.359.
[27]	RAMAN S, FITZGERALD U, MURPHY J M. Interplay of inflammatory mediators with epigenetics and cartilage modifications in osteoarthritis[J]. Front Bioeng Biotechnol, 2018, 6: 22. DOI: 10.3389/fbioe.2018.00022.
[28]	NAGAHASHI M, YAMADA A, KATSUTA E, et al. Targeting the SphK1/S1P/S1PR1 axis that links obesity, chronic inflammation, and breast cancer metastasis[J]. Cancer Res, 2018, 78(7): 1713-1725. DOI: 10.1158/0008-5472.CAN-17-1423.
[29]	DRUCKER D J. GLP-1 physiology informs the pharmacotherapy of obesity[J]. Mol Metab, 2022, 57: 101351. DOI: 10.1016/j.molmet.2021.101351.
[30]	HEPPNER K M, KIRIGITI M, SECHER A, et al. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain[J]. Endocrinology, 2015, 156(1): 255-267. DOI: 10.1210/en.2014-1675.
[31]	KIM K S, PARK J S, HWANG E, et al. GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans[J]. Science, 2024, 385(6707): 438-446. DOI: 10.1126/science.adj2537.
[32]	SINGH I, WANG L, XIA B J, et al. Activation of arcuate nucleus glucagon-like peptide-1 receptor-expressing neurons suppresses food intake[J]. Cell Biosci, 2022, 12(1): 178. DOI: 10.1186/s13578-022-00914-3.
[33]	HUANG Z H, LIU L, ZHANG J, et al. Glucose-sensing glucagon-like peptide-1 receptor neurons in the dorsomedial hypothalamus regulate glucose metabolism[J]. Sci Adv, 2022, 8(23): eabn5345. DOI: 10.1126/sciadv.abn5345.
[34]	KABAHIZI A, WALLACE B, LIEU L, et al. Glucagon-like peptide-1 (GLP-1) signalling in the brain: from neural circuits and metabolism to therapeutics[J]. Br J Pharmacol, 2022, 179(4): 600-624. DOI: 10.1111/bph.15682.
[35]	HE Z Y, GAO Y, LIEU L, et al. Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons-Implications for energy balance and glucose control[J]. Mol Metab, 2019, 28: 120-134. DOI: 10.1016/j.molmet.2019.07.008.
[36]	BU T, SUN Z Y, PAN Y, et al. Glucagon-like peptide-1: new regulator in lipid metabolism[J]. Diabetes Metab J, 2024, 48(3): 354-372. DOI: 10.4093/dmj.2023.0277.
[37]	XU X Y, WANG J X, CHEN J L, et al. GLP-1 in the hypothalamic paraventricular nucleus promotes sympathetic activation and hypertension[J]. J Neurosci, 2024, 44(21): e2032232024. DOI: 10.1523/jneurosci.2032-23.2024.
[38]	YAN M L, SHI W H, GONG P, et al. A U-shaped non-linear association between serum uric acid levels and the risk of Hashimoto's thyroiditis: a cross-sectional study[J]. Front Endocrinol (Lausanne), 2025, 16: 1514857. DOI: 10.3389/fendo.2025.1514857.
[39]	KUMAR V. GLP-1/GLP-1R axis: from metabolism (obesity and T2DM) to immunity[J]. Open Biol, 2025, 15(7): 240303. DOI: 10.1098/rsob.240303.
[40]	FISMAN E Z, TENENBAUM A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect[J]. Cardiovasc Diabetol, 2021, 20(1): 225. DOI: 10.1186/s12933-021-01412-5.
[41]	SCHEEN A J. Dual GIP/GLP-1 receptor agonists: new advances for treating type-2 diabetes[J]. Ann Endocrinol (Paris), 2023, 84(2): 316-321. DOI: 10.1016/j.ando.2022.12.423.
[42]	BAGGIO L L, DRUCKER D J. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease[J]. Mol Metab, 2021, 46: 101090. DOI: 10.1016/j.molmet.2020.101090.
[43]	JAMES-OKORO P P, LEWIS J E, GRIBBLE F M, et al. The role of GIPR in food intake control[J]. Front Endocrinol (Lausanne), 2025, 16: 1532076. DOI: 10.3389/fendo.2025.1532076.
[44]	LISKIEWICZ A, MÜLLER T D. Regulation of energy metabolism through central GIPR signaling[J]. Peptides, 2024, 176: 171198. DOI: 10.1016/j.peptides.2024.171198.
[45]	LAFFERTY R A, FLATT P R, GAULT V A, et al. Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes [J]. J Endocrinol, 2024, 262(2): e230339. DOI: 10.1530/JOE-23-0339.
[46]	CHEN X Y, HE X Y, GUO Y, et al. Glucose-dependent insulinotropic polypeptide modifies adipose plasticity and promotes beige adipogenesis of human omental adipose-derived stem cells[J]. FASEB J, 2021, 35(5): e21534. DOI: 10.1096/fj.201903253R.
[47]	ENGLISH A, CRAIG S L, FLATT P R, et al. Individual and combined effects of GIP and xenin on differentiation, glucose uptake and lipolysis in 3T3-L1 adipocytes[J]. Biol Chem, 2020, 401(11): 1293-1303. DOI: 10.1515/hsz-2020-0195.
[48]	VASILEVA A, MARX T, BEAUDRY J L, et al. Glucagon receptor signaling at white adipose tissue does not regulate lipolysis[J]. Am J Physiol Endocrinol Metab, 2022, 323(4): E389-E401. DOI: 10.1152/ajpendo.00078.2022.
[49]	JIA Y B, LIU Y, FENG L L, et al. Role of glucagon and its receptor in the pathogenesis of diabetes[J]. Front Endocrinol (Lausanne), 2022, 13: 928016. DOI: 10.3389/fendo.2022.928016.
[50]	ZHENG Y, WANG Y R, XIONG X, et al. CD9 counteracts liver steatosis and mediates GCGR agonist hepatic effects[J]. Adv Sci (Weinh), 2024, 11(29): e2400819. DOI: 10.1002/advs.202400819.
[51]	BEAUDRY J L, KAUR K D, VARIN E M, et al. The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice[J]. Mol Metab, 2019, 22: 37-48. DOI: 10.1016/j.molmet.2019.01.011.
[52]	ZHANG X L, CAI Y C, YAO Z H, et al. Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists[J]. Peptides, 2023, 161: 170948. DOI: 10.1016/j.peptides.2023.170948.
[53]	URQUHART S, WILLIS S. Long-acting GLP-1 receptor agonists: findings and implications of cardiovascular outcomes trials[J]. JAAPA, 2020, 33(S8 Suppl 1): 19-30. DOI: 10.1097/01.JAA.0000669452.63883.45.
[54]	NANNA M G, DOAN Q V, FABRICATORE A, et al. Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: a modelling study based on the SELECT trial[J]. Diabetes Obes Metab, 2025, 27(6): 3442-3452. DOI: 10.1111/dom.16370.
[55]	WONG N D, KARTHIKEYAN H, FAN W J. US population eligibility and estimated impact of semaglutide treatment on obesity prevalence and cardiovascular disease events[J]. Cardiovasc Drugs Ther, 2025, 39(1): 75-84. DOI: 10.1007/s10557-023-07488-3.
[56]	DE FARIA MORAES B, ANDRÉ PEDRAL DINIZ LEITE G, ANDRÉ PEDRAL DINIZ LEITE G, et al. Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption and liver-related outcomes: a systematic review and meta-analysis[J]. Drug Alcohol Depend, 2025, 275: 112840. DOI: 10.1016/j.drugalcdep.2025.112840.
[57]	ANDERER S. FDA approves semaglutide to reduce risk of kidney disease progression[J]. JAMA, 2025. DOI: 10.1001/jama.2025.0548.
[58]	YANG Q, QIN C M, LANG Y L, et al. Effectiveness of sodium-glucose transporter 2 inhibitors and semaglutide on body composition in type 2 diabetes mellitus and chronic kidney disease: a real-world cohort study with bioelectrical impedance analysis[J]. Diabetes Metab Syndr Obes, 2025, 18: 2885-2897. DOI: 10.2147/DMSO.S531413.
[59]	ATIQUZZAMAN N, RAZDOLSKY N, PARMAR M S. GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management-current evidence and future outlook[J]. Eur J Clin Pharmacol, 2025, 81(11): 1569-1581. DOI: 10.1007/s00228-025-03898-4.
[60]	HELAL M M, ABOUSHAWAREB H, ABBAS O H, et al. GLP-1 receptor agonists in Parkinson's disease: an updated comprehensive systematic review with meta-analysis[J]. Diabetol Metab Syndr, 2025, 17(1): 352. DOI: 10.1186/s13098-025-01888-1.
[61]	LIU K, LIU S, WANG D, et al. Are GLP-1 receptor agonists and diabetic retinopathy foes or friends [J]. Diabetes Metab, 2025, 51(6): 101696. DOI: 10.1016/j.diabet.2025.101696.
[62]	DAI H, LI Y Q, LEE Y A, et al. GLP-1 receptor agonists and cancer risk in adults with obesity[J]. JAMA Oncol, 2025, 11(10): 1186-1193. DOI: 10.1001/jamaoncol.2025.2681.
[63]	ZHONG Y, WU T T, KHAN N U. Association between GLP-1 receptor agonists as a class and colorectal cancer risk: a meta-analysis of retrospective cohort studies[J]. BMC Gastroenterol, 2025, 25(1): 614. DOI: 10.1186/s12876-025-04211-4.
[64]	WANG M, CHEN X H, LIU Z Q, et al. Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data[J]. EClinicalMedicine, 2025, 86: 103385. DOI: 10.1016/j.eclinm.2025.103385.
[65]	STOJKOVSKA A, RUS PRELOG P, KOKALJ PALANDACIC A. Association of semaglutide use with depressive symptoms and suicidal behavior in a patient with type 2 diabetes: a case report[J]. J Int Med Res, 2025, 53(7): 3000605251349393. DOI: 10.1177/03000605251349393.
[66]	GAMBORG M, GRAND M K, GRELL K, et al. Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trial[J]. Lancet Reg Health Eur, 2025, 55: 101346. DOI: 10.1016/j.lanepe.2025.101346.
[67]	LI Y, ZHOU Q T, DAI A T, et al. Structural analysis of the dual agonism at GLP-1R and GCGR[J]. Proc Natl Acad Sci USA, 2023, 120(33): e2303696120. DOI: 10.1073/pnas.2303696120.
[68]	LAKER R C, EGOLF S, WILL S, et al. GLP-1R/GCGR dual agonism dissipates hepatic steatosis to restore insulin sensitivity and rescue pancreatic β-cell function in obese male mice[J]. Nat Commun, 2025, 16: 4714. DOI: 10.1038/s41467-025-59773-4.
[69]	BOLAND M L, LAKER R C, MATHER K, et al. Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis[J]. Nat Metab, 2020, 2(5): 413-431. DOI: 10.1038/s42255-020-0209-6.
[70]	XIA H M, MIN Y Q, WANG Y H, et al. Multiparametric MRI evaluation of liver fat and iron after glucagon-like peptide-1 receptor and glucagon receptor dual-agonist treatment in a high-fat diet-induced mouse model[J]. Radiology, 2025, 316(2): e243780. DOI: 10.1148/radiol.243780.
[71]	JI L N, JIANG H W, BI Y, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight[J]. N Engl J Med, 2025, 392(22): 2215-2225. DOI: 10.1056/NEJMoa2411528.
[72]	JI L N, GAO L L, JIANG H W, et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 Mg and 10 Mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial[J]. EClinicalMedicine, 2022, 54: 101691. DOI: 10.1016/j.eclinm.2022.101691.
[73]	BHATTACHAR S N, THAM L S, LI Y, et al. Mazdutide reduces body weight in adults with overweight or obesity: a high-dose Phase 1 trial[J]. Diabetes Obes Metab, 2025, 27(11): 6460-6469. DOI: 10.1111/dom.70040.
[74]	DONG W Q, BAI J, YUAN Q B, et al. Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis[J]. eBioMedicine, 2025, 117: 105791. DOI: 10.1016/j.ebiom.2025.105791.
[75]	PENG L J, LAI W J, YU S J, et al. GLP-1 and glucagon receptor dual agonism ameliorates kidney allograft fibrosis by improving lipid metabolism[J]. Front Immunol, 2025, 16: 1551136. DOI: 10.3389/fimmu.2025.1551136.
[76]	HUANG P, MENG L Z, TAN J H, et al. S3-2, a novel long-lasting oxyntomodulin derivative, exerts improvement on diabesity and renal injury through activating GLP-1 and glucagon receptors[J]. Life Sci, 2021, 270: 119136. DOI: 10.1016/j.lfs.2021.119136.
[77]	DING W X, WANG H Y, PENG L J, et al. Novel peptidic dual GLP-1/glucagon receptor agonist alleviates diabetes and diabetic complications in combination with low-intensity ultrasound[J]. Eur Rev Med Pharmacol Sci, 2020, 24(23): 12423-12436. DOI: 10.26355/eurrev_202012_24038.
[78]	RODRIGUEZ R, HERGARDEN A, KRISHNAN S, et al. Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy[J]. Cell Rep Med, 2025, 6(6): 102156. DOI: 10.1016/j.xcrm.2025.102156.
[79]	XIE Z Y, LIANG Z R, XIE Y L, et al. Comparative safety of GLP-1/GIP co-agonists versus GLP-1 receptor agonists for weight loss in patients with obesity or overweight: a systematic review[J]. Diabetes Metab Syndr Obes, 2025, 18: 2837-2849. DOI: 10.2147/DMSO.S537229.
[80]	YAMAGUCHI Y, KUWATA H, IMURA M, et al. Early induction of insulin sensitisation treated by tirzepatide: a prospective, single-arm, open-label study in Japanese individuals with obesity and type 2 diabetes[J]. Diabetologia, 2025, 68(10): 2151-2155. DOI: 10.1007/s00125-025-06493-5.
[81]	LI Y, SUN W C, LIU H, et al. Tirzepatide, a dual GIP/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A[J]. Genes Dis, 2025, 12(6): 101761. DOI: 10.1016/j.gendis.2025.101761.
[82]	AYDOS D, AKSOY Z B, UNAL M A, et al. The dual GLP-1 and GIP receptor agonist tirzapetide provides an unintended interaction with the β-adrenoceptors and plays a role in glucose metabolism in hyperglycemic or senescent cardiac cells[J]. Cardiovasc Diabetol, 2025, 24(1): 338. DOI: 10.1186/s12933-025-02828-z.
[83]	KRAMER C M, BORLAUG B A, ZILE M R, et al. Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: summit CMR substudy[J]. J Am Coll Cardiol, 2025, 85(7): 699-706. DOI: 10.1016/j.jacc.2024.11.001.
[84]	GOLDNEY J, HAMZA M, SURTI F, et al. Triple agonism based therapies for obesity[J]. Curr Cardiovasc Risk Rep, 2025, 19(1): 18. DOI: 10.1007/s12170-025-00770-z.
[85]	MISRA S, NARAYAN R K, KAUR M. Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials[J]. J Basic Clin Physiol Pharmacol, 2025, 36(4): 263-274. DOI: 10.1515/jbcpp-2025-0113.
[86]	COSKUN T, URVA S, ROELL W C, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept[J]. Cell Metab, 2022, 34(9): 1234-1247.e9. DOI: 10.1016/j.cmet.2022.07.013.
[87]	COSKUN T, WU Q W, SCHLOOT N C, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial[J]. Lancet Diabetes Endocrinol, 2025, 13(8): 674-684. DOI: 10.1016/S2213-8587(25)00092-0.
[88]	WEN Y, LEMEN D, LIN Y Z, et al. Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids[J]. Diabetes Obes Metab, 2025, 27(10): 5985-5995. DOI: 10.1111/dom.16661.
[89]	KUMARI A, LARSEN S W R, BONDESEN S, et al. ANGPTL3/8 is an atypical unfoldase that regulates intravascular lipolysis by catalyzing unfolding of lipoprotein lipase[J]. Proc Natl Acad Sci USA, 2025, 122(12): e2420721122. DOI: 10.1073/pnas.2420721122.
[90]	LEANDER K, CHEN Y Q, VIKSTRÖM M, et al. Circulating ANGPTL3/8 concentrations are associated with an atherogenic lipoprotein profile and increased CHD risk in Swedish population-based studies[J]. Arterioscler Thromb Vasc Biol, 2025, 45(3): 443-451. DOI: 10.1161/ATVBAHA.124.321308.
[91]	CHAN D C, WATTS G F. Inhibition of the ANGPTL3/8 complex for the prevention and treatment of atherosclerotic cardiovascular disease[J]. Curr Atheroscler Rep, 2024, 27(1): 6. DOI: 10.1007/s11883-024-01254-y.

A New Chapter in Obesity Treatment: Mechanisms and Clinical Research Progress of Multi-target Peptide Agonists

肥胖症治疗的新篇章：多靶点肽类激动剂的机制与临床研究进展

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 91

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	CHEN Xiaolong, JIN Jing, HUA Jialu, LI Yuyu, PAN Youjia, PAN Qi, TU Chunjing, WANG Ping. Study on the Optimal Time-use Composition of 24-hour Movement Behaviors for Obesity Prevention in College Students [J]. Chinese General Practice, 2026, 29(12): 1525-1532.
[2]	YANG Lei, GUAN Hua. Application Progress of Generative Artificial Intelligence in Weight Management [J]. Chinese General Practice, 2026, 29(12): 1533-1540.
[3]	HE Zhiguang, QIU Shanjiao, CHEN Zhang, LI Anchun, HUANG Wenjing. Interpretation and Discussion of the RACGP Guidelines for Preventive Activities in General Practice: Screening for Weight Issues and Preventive Strategies [J]. Chinese General Practice, 2026, 29(12): 1505-1510.
[4]	GU Handong, LU Hongrun, GU Keyi, HAN Zheng, YANG Fei, FU Xiaoya, WANG Weiqiang. Association Research between Relative Fat Mass and the Incidence Risk of Cardiometabolic Multimorbidity [J]. Chinese General Practice, 2026, 29(11): 1456-1462.
[5]	SUN Xia, SHEN Wen, TANG Xiang, ZHONG Wei, WANG Kailin, DAI Zhiyin, ZHANG Chaopu, YUAN Wei, YUAN Guoyue. Analysis of Clinical Characteristics in Dilated Cardiomyopathy Patients with Different Weight Statuses and the Influence of Weight Management on the Prognosis [J]. Chinese General Practice, 2026, 29(11): 1448-1455.
[6]	ZHANG Sanhua, CHEN Xiaolong, ZHANG Yanfeng. BMI Percentile Reference Curves and Trends in Thinness, Overweight, and Obesity among Preschool Children in Macao [J]. Chinese General Practice, 2026, 29(09): 1146-1154.
[7]	ZHANG Qiuyu, HU Xiaoyong, TANG Rui, LI Hongjian. Correlation between Chinese Visceral Adiposity Index and Nocturnal Hypertension in Young and Middle-aged People [J]. Chinese General Practice, 2026, 29(07): 872-878.
[8]	HAN Zheng, FU Fanglin, SUN Meng, PAN Yaojia, WANG Weiqiang. A Cross-sectional Study on the Relationship between the Chinese Visceral Adiposity Index and Cardiometabolic Multimorbidity in Individuals Aged 60 and Above [J]. Chinese General Practice, 2026, 29(06): 693-698.
[9]	ZHANG Zhiwei, HE Panpan, YANG Qianwen, JIN Xueyi, MAO Xueqian, HU Ying, JING Lipeng. The Relationship between Different Obesity Indicators and Frailty among the Elderly in Rural Regions [J]. Chinese General Practice, 2026, 29(06): 699-709.
[10]	CHEN Zhixin, ZHANG Li, GUO Xinyue, ZHOU Zhongliang, ZHANG Jianduan, XU Jinhang, RONG Shengzhong, ZHAO Li, TIAN Qiyue, WANG Sufang, TIAN Xiangyang, GONG Shaoqing. Study on Dietary Factors Associated with Obesity Among University Freshmen [J]. Chinese General Practice, 2026, 29(03): 361-372.
[11]	SHENG Luguang, LIU Dandan, LIU Weibin, LU Jun, LEI Tao, CHEN Qingguang, LU Hao, XU Bilin. Effects of Short-term Dietary Intervention for Obese Patients with Abnormal Glucose Metabolism [J]. Chinese General Practice, 2026, 29(03): 373-379.
[12]	ZHANG Ying, YANG Ziyu, LIU Lidi, LIAO Xiaoyang, JIA Yu, SHEN Can, YANG Rong. Interpretation of the Consensus Statement Physical by American College of Sports Medicine on Adults Activity and Excess Body Weight and Adiposity [J]. Chinese General Practice, 2026, 29(03): 293-298.
[13]	ZHANG Wei, JIA Yuexiao, TANG Hongwei, XUE Xin, LEI Ying, DU Na, WANG Yumeng, YUAN Jiyun, LIU Huan. Study on the Effect of Energy-limited Intermittent Diet Patterns on Weight Management in Overweight and Obese People [J]. Chinese General Practice, 2026, 29(03): 355-360.
[14]	LI Jixin, QIU Linjie, REN Yan, WANG Wenru, YANG Zhenyu, LIU Fengzhao, LI Meijie, LI Wenjie, ZHANG Jin. Correlation of Muscle-fat Ratio with Non-obese Hyperuricaemia and the Predictive Value [J]. Chinese General Practice, 2026, 29(01): 84-90.
[15]	XU Chunyan, HE Ling, GUO Canhui, LAI Hurong, LIAO Caifeng, TU Huaijun. Associations of Lipid Levels and the Risk of Sarcopenic Obesity in Middle-aged and Elderly Chinese: a Cohort Study [J]. Chinese General Practice, 2025, 28(33): 4125-4131.